Evidence supporting the use of: Ostarine
For the health condition: Muscular Dystrophy
Synopsis
Source of validity: Scientific
Rating (out of 5): 2
Ostarine (also known as MK-2866 or Enobosarm) is a selective androgen receptor modulator (SARM) that has garnered research interest for the treatment of muscle-wasting conditions, including muscular dystrophy. The rationale for its use is based on its ability to selectively stimulate androgen receptors in muscle and bone, potentially increasing muscle mass and function with fewer side effects compared to traditional anabolic steroids. Several early-phase clinical trials have investigated Ostarine in populations with muscle wasting due to cancer, aging, or other chronic illnesses, showing modest increases in lean body mass and some functional improvements. However, data specifically in muscular dystrophy patients is extremely limited. There have been preclinical studies in animal models suggesting potential benefit, but robust, peer-reviewed clinical trials in humans with muscular dystrophy are lacking as of 2024. Regulatory agencies have not approved Ostarine for muscular dystrophy, and concerns remain about its long-term safety and potential for adverse effects. While there is a scientific rationale and some preliminary evidence supporting its anabolic effects, the direct evidence for its efficacy and safety in muscular dystrophy is insufficient, resulting in a low evidence rating.
Other ingredients used for Muscular Dystrophy
acetyl l-carnitinecoenzyme Q10 (CoQ10)
creatine monohydrate
turmeric
omega-3 fatty acids
Urolithin A
vitamin D
Arginine Creatine
Creatine